Technical Analysis for EGLTQ - Egalet Corp

Grade Last Price % Change Price Change
grade B 0.0083 -11.70% -0.0011
EGLTQ closed down 11.7 percent on Friday, February 1, 2019, on 0 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Up Down
See historical EGLTQ trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Crossed Above 20 DMA Bullish -11.70%
Crossed Above 50 DMA Bullish -11.70%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -11.70%
NR7 Range Contraction -11.70%

Older signals for EGLTQ ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Egalet Corporation, a specialty pharmaceutical company, develops, manufactures, and commercializes treatments for patients with pain and other conditions. It has licensed three approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; OXAYDO, an immediate-release oxycodone product designed to discourage abuse via snorting for the management of acute and chronic pain severe enough to require an opioid analgesic, and for which alternative treatments are inadequate; and ARYMO ER, an extended-release (ER) morphine product formulated with abuse-deterrent (AD) properties for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The company is also developing Egalet-002, a Guardian Technology AD, ER, oral oxycodone formulation, which is in Phase III clinical trials for the same indication as ARYMO ER. In addition, its other products include Egalet-003, an AD stimulant product candidate; and Egalet-004, an AD, ER hydrocodone-based product candidate. The company has a collaboration and license agreement with Acura Pharmaceuticals, Inc. to commercialize OXAYDO tablets; and Septodont, Inc. to promote SPRIX Nasal Spray. Egalet Corporation was founded in 2010 and is headquartered in Wayne, Pennsylvania.
RTT Euphoriants Pharmaceutical Psychoactive Drugs Chemical Compounds Morphinans Heroin Opioids Morphine Oxycodone Acute And Chronic Pain Analgesic Pain Products Alternative Treatments Hydrocodone Immediate Release Oxycodone Product Morphine Product Nasal Spray Short Term Management Sprix Nasal Spray
Is EGLTQ a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicator Value
52 Week High 0.038
52 Week Low 0.001
Average Volume 289,328
200-Day Moving Average 0.0
50-Day Moving Average 0.0075
20-Day Moving Average 0.0082
10-Day Moving Average 0.0115
Average True Range 0.0028
ADX 27.74
+DI 20.3608
-DI 16.7526
Chandelier Exit (Long, 3 ATRs ) 0.0065
Chandelier Exit (Short, 3 ATRs ) 0.0105
Upper Bollinger Band 0.0157
Lower Bollinger Band 0.0007
Percent B (%b) 0.51
BandWidth 182.926829
MACD Line 0.0007
MACD Signal Line 0.0006
MACD Histogram 0.0001
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0083
Resistance 3 (R3) 0.0083 0.0083 0.0083
Resistance 2 (R2) 0.0083 0.0083 0.0083 0.0083
Resistance 1 (R1) 0.0083 0.0083 0.0083 0.0083 0.0083
Pivot Point 0.0083 0.0083 0.0083 0.0083 0.0083
Support 1 (S1) 0.0083 0.0083 0.0083 0.0083 0.0083
Support 2 (S2) 0.0083 0.0083 0.0083 0.0083
Support 3 (S3) 0.0083 0.0083 0.0083
Support 4 (S4) 0.0083